Incidence of pediatric inflammatory bowel disease in Saudi Arabia: a multicenter national study.

Inflamm Bowel Dis

1Department of Pediatrics, Division of Gastroenterology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia; 2Department of Pediatrics, Division of Gastroenterology, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia; 3Department of Pediatrics, Division of Gastroenterology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 4Department of Pediatrics, Division of Gastroenterology, Dhahran Health Center, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia; 5Department of Pediatrics, Division of Gastroenterology, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia; 6Department of Pediatrics, Division of Gastroenterology, King Fahad Specialist Hospital, Dammam, Saudi Arabia; 7Department of Pediatrics, Division of Gastroenterology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia; 8Department of Gastroenterology, Al-Mofarreh Polyclinic, Riyadh, Saudi Arabia; 9Division of Gastroenterology, King Fahad Medical City, Children's Hospital, Riyadh, Saudi Arabia; 10Department of Medicine, Division of Gastroenterology, King Fahd Hospital of the University, University of Dammam, Al Khobar, Saudi Arabia; 11Department of Pediatrics, Division of Gastroenterology, Al-Noor Specialist Hospital, Makkah, Saudi Arabia; 12Division of Gastroenterology, Maternity and Children's Hospital, Madinah, Saudi Arabia; 13Department of Pediatrics, Division of Gastroenterology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; 14Division of Gastroenterology, Maternity and Children's Hospital, Dammam, Saudi Arabia; 15Division of Gastroenterology, Makkah Maternity and Children's Hospital, Makkah, Saudi Arabia; and 16Department of Pediatrics, Division of Gastroenterology, Prince Sultan Military Medical City. Riyadh, Saudi Arabia.

Published: June 2014

Background: Pediatric inflammatory bowel disease (IBD) is increasingly recognized in developing countries; however, the incidence and trend over time have not been reported.

Methods: This retrospective study included children diagnosed with IBD in gastroenterology centers in the Kingdom of Saudi Arabia between 2003 and 2012. The date of birth, date and age at diagnosis, gender, and final diagnosis were collected on special forms. Clinical, laboratory, imaging, endoscopy, and histopathology results were reviewed to confirm the final diagnosis. Descriptive statistics were used to compare ulcerative colitis and Crohn's disease in different age groups, and significance was assessed by the chi-square test. Incidence rates and trend over time were analyzed with the assumption of Poisson distribution. The incidence rate over time was compared in 2 periods (2003-2007 and 2008-2012). A P value of <0.05 and 95% confidence intervals were used to assess the significance and precision of the estimates.

Results: A total of 340 Saudi Arabian children aged 0 to 14 years were diagnosed. The mean incidence rate per 100,000 individuals was 0.2, 0.27, and 0.47 for ulcerative colitis, Crohn's disease, and IBD, respectively. Except for the 0- to 4-year age group, there was a significant increase in incidence over time.

Conclusions: Although the incidence of pediatric IBD in Saudi Arabian children is lower than suggested in the Western literature, there is a significantly increasing trend over time. However, decreased trend in the younger age group over time is identified. Prospective studies will be important to identify the risk factors for IBD in different age groups.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MIB.0000000000000048DOI Listing

Publication Analysis

Top Keywords

pediatric inflammatory
8
inflammatory bowel
8
bowel disease
8
saudi arabia
8
trend time
8
final diagnosis
8
incidence
4
incidence pediatric
4
disease saudi
4
arabia multicenter
4

Similar Publications

Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study.

BMC Gastroenterol

December 2024

Department of Gastroenterology and Hepatology, Linkou Branch, Chang Gung Memorial Hospital, 5, Fu-Hsin Street, Guei-Shan District, Taoyuan, 33305, Taiwan.

Background/aims: The increasing use of biologic therapies for moderate to severe inflammatory bowel disease (IBD) highlights the importance of optimal treatment sequencing, particularly after vedolizumab (VDZ) exposure. Studies comparing the effectiveness of ustekinumab (UST) and antitumor necrosis factor (anti-TNF) agents post-VDZ are limited.

Methods: This retrospective study analyzed VDZ-experienced IBD patients treated with UST or anti-TNF (adalimumab and infliximab) from May 2019 to January 2024.

View Article and Find Full Text PDF

NRP1 instructs IL-17-producing ILC3s to drive colitis progression.

Cell Mol Immunol

January 2025

Department of oncology, The Second Hospital of Tianjin Medical University; Tianjin Key Laboratory of Precision Medicine for Sex Hormones and Diseases; Tianjin Institute of Immunology, Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

Group 3 innate lymphoid cells (ILC3s) control tissue homeostasis and orchestrate mucosal inflammation; however, the precise mechanisms governing ILC3 activity are fully understood. Here, we identified the transmembrane protein neuropilin-1 (NRP1) as a positive regulator of interleukin (IL)-17-producing ILC3s in the intestine. NRP1 was markedly upregulated in intestinal mucosal biopsies from patients with inflammatory bowel disease (IBD) compared with healthy controls.

View Article and Find Full Text PDF

Risk Factors and Treatment Strategies for Anastomotic Ulcers in Pediatric Intestinal Failure.

J Pediatr Surg

December 2024

Department of Surgery, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

Purpose: Anastomotic ulcers (AUs) are a rare cause of morbidity in intestinal failure (IF). Prior studies of AUs have been small, descriptive reports. We evaluated a large cohort of IF patients to identify risk factors and describe treatment strategies for AUs.

View Article and Find Full Text PDF

Background: Dermatophytosis caused by Nannizzia gypsea are considered rare. The clinical picture is indistinguishable from that produced by other dermatophytes, but, being this a geophilic fungus, it can cause more inflammatory disease.

Methods: Retrospective study.

View Article and Find Full Text PDF

Eczema is also known as atopic dermatitis, which goes on to affect the skin as a chronic inflammatory disease. It is associated with a constant feeling of scratchiness, erthyma and disruption of the natural skin barrier. Treatment provided at present may improve some of the symptoms, for instance use of corticosteroids or immunosuppressive agents, however, there is an overwhelming need for better focused and effective methods of treatment with minimal adverse effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!